Iftekhar Kalsekar, PhD

home / authors / iftekhar-kalsekar-phd

Articles

April 19th 2017

The Relationship Between Adherence and Total Spending Among Medicare Beneficiaries With Type 2 Diabetes

Joanna P. MacEwan, PhD John J Sheehan, PhD Wes Yin, PhD Jacqueline Vanderpuye-Orgle, PhD Jeffrey Sullivan, MS Desi Peneva, MS Iftekhar Kalsekar, PhD Anne L Peters, MD

This study describes a widespread variation in medication adherence, pharmacy cost sharing, and medical spending. Increased cost sharing may decrease adherence and increase total diabetes spending.

September 20th 2016

Representativeness of Dipeptidyl-Peptidase-4 Inhibitor Cardiovascular Outcomes Trials

Joanna P. MacEwan, PhD John J Sheehan, PhD Anne Peters, MD Jacqueline Vanderpuye-Orgle, PhD Iftekhar Kalsekar, PhD Anup Malani, PhD

Given the growing prevalence of type 2 diabetes (T2D) and its contribution to cardiovascular disease, cardiovascular outcomes trials should aim to be more representative of the average patient with T2D.

February 24th 2014

Formulary Restrictions on Atypical Antipsychotics: Impact on Costs for Patients With Schizophrenia and Bipolar Disorder in Medicaid

Seth A. Seabury, PhD Dana P. Goldman, PhD Iftekhar Kalsekar, PhD John J Sheehan, PhD Kimberly Laubmeier, PhD Darius N. Lakdawalla, PhD

Retrospective analysis of medical and pharmacy claims for patients diagnosed with schizophrenia or bipolar disorder in 24 state Medicaid programs.